Find information on thousands of medical conditions and prescription drugs.

Fulvestrant

Fulvestrant is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects and down-regulates the estrogen receptor. It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


New treatment for advanced breast cancer - Updates
From FDA Consumer, 7/1/02

In April 2002, the FDA approved Faslodex (fulvestrant) for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women whose disease progresses following anti-estrogen therapy.

In this type of breast cancer, estrogen can stimulate the growth of tumors by entering cells at multiple sites called estrogen receptors. Faslodex inhibits this action of estrogen and appears to reduce the number of estrogen receptors in breast cancer cells.

Faslodex was found to be as effective as the drug anastrozole in two randomized, controlled clinical trials in postmenopausal women with locally advanced or metastatic breast cancer that progressed following treatment with tamoxifen. Anastrozole is another drug used to decrease estrogen production and suppress the growth of tumors that need estrogen to grow. Faslodex is administered as a monthly injection into the buttocks.

The most commonly reported side effects were nausea, headache, back pain, vomiting, constipation, diarrhea, abdominal pain, hot flushes, and pharyngitis (inflammation of the throat), regardless of whether patients were treated with Faslodex injections or anastrozole tablets. Pain at the site of the injection was reported in about 10 percent of patients treated with Faslodex.

Faslodex is indicated for postmenopausal women and should not be given to pregnant women because of the risk of harm to a fetus.

Faslodex is distributed in the United States by AstraZeneca Pharmaceuticals LP, Wilmington, Del.

COPYRIGHT 2002 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group

Return to Fulvestrant
Home Contact Resources Exchange Links ebay